Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 47.0% in March

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOSGet Ranking) was the goal of a substantial progress in brief interest in March. As of March 31st, there was short interest totalling 1,690,000 shares, a growth of 47.% from the March 15th full of 1,150,000 shares. Approximately 6.9% of the shares of the enterprise are short bought. Based on an typical day-to-day quantity of 260,200 shares, the days-to-protect ratio is presently 6.5 days.

NASDAQ:ABOS opened at $3.97 on Friday. The company’s 50-working day moving common price is $5.19 and its 200-day transferring common cost is $7.92. Acumen Prescribed drugs has a twelve month very low of $3.67 and a twelve month substantial of $26.98.

ABOS has been the subject of quite a few latest investigation stories. Lender of America lifted shares of Acumen Prescription drugs from a “neutral” rating to a “buy” ranking and dropped their value objective for the corporation from $16.00 to $14.00 in a report on Friday, January 21st. Zacks Investment decision Exploration downgraded shares of Acumen Pharmaceuticals from a “buy” rating to a “hold” ranking in a report on Tuesday, April 5th. Eventually, Credit rating Suisse Group cut their rate concentrate on on Acumen Pharmaceuticals from $26.00 to $17.00 and established an “outperform” score for the corporation in a research observe on Tuesday, March 29th. A person expenditure analyst has rated the stock with a hold rating and 4 have issued a buy rating to the company’s stock. According to details from MarketBeat, Acumen Pharmaceuticals has a consensus rating of “Buy” and an regular selling price target of $18.35.

Institutional traders have not long ago built improvements to their positions in the stock. Citigroup Inc. enhanced its holdings in shares of Acumen Pharmaceuticals by 255.7% all through the 4th quarter. Citigroup Inc. now owns 3,891 shares of the company’s inventory worthy of $26,000 immediately after acquiring an extra 2,797 shares throughout the last quarter. California Condition Instructors Retirement Process bought a new stake in Acumen Prescribed drugs in the 3rd quarter valued at approximately $77,000. American Intercontinental Group Inc. obtained a new posture in Acumen Prescription drugs during the 3rd quarter truly worth $78,000. New York Point out Common Retirement Fund acquired a new posture in Acumen Pharmaceuticals through the fourth quarter really worth $37,000. At last, Deutsche Lender AG obtained a new situation in Acumen Prescription drugs during the 3rd quarter value $82,000. Hedge resources and other institutional buyers individual 65.55% of the company’s inventory.

About Acumen Pharmaceuticals (Get Score)

Acumen Prescribed drugs, Inc, a clinical-phase biopharmaceutical organization, engages in the improvement of therapeutics for the therapy of Alzheimer’s and other neurodegenerative health conditions. The corporation focuses on advancing a focused immunotherapy drug prospect ACU193, which is in Phase I clinical-stage to focus on soluble amyloid-beta oligomers.

Featured Tales

Obtain News & Ratings for Acumen Prescription drugs Each day – Enter your e-mail tackle down below to obtain a concise each day summary of the most current information and analysts’ scores for Acumen Pharmaceuticals and relevant corporations with’s Free everyday e-mail e-newsletter.